GLP-1 for PCOS

1. Why PCOS is really an insulin problem

PCOS is defined clinically by some combination of irregular cycles, biochemical or clinical hyperandrogenism, and polycystic ovarian morphology — the Rotterdam criteria. But underneath those diagnostic markers, the dominant mechanism in the majority of cases is insulin resistance.

Insulin and IGF-1 signal directly on ovarian theca cells. Chronically elevated insulin pushes androgen synthesis up and suppresses hepatic production of sex-hormone binding globulin (SHBG), which raises free testosterone and amplifies the phenotype. The downstream effects are familiar to anyone who has lived with PCOS: irregular ovulation, hirsutism, acne, abdominal weight retention, and metabolic markers that drift toward prediabetes over the years.

Address the insulin resistance and the cascade downstream tends to improve. That is why metformin has been in PCOS care for decades, and why even modest weight loss has been shown to restore ovulation in many PCOS patients in landmark lifestyle trials.

2. The 2023 International PCOS Guideline — what it actually says

The 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — co-published by ESHRE, the Endocrine Society, the ASRM, and the Monash Centre for Health Research — is the current global standard-of-care document for PCOS.

The guideline conditionally recommends GLP-1 receptor agonists as an option for weight management in women with PCOS who have not responded sufficiently to lifestyle intervention. The guideline is careful: GLP-1 is not first-line, lifestyle remains the foundation, and contraception counseling is required for any reproductive-age woman on therapy. But it formally moved GLP-1 from off-protocol to inside the international standard.

3. The 2024 Cena meta-analysis — reading the headline numbers

Cena et al. (2024) pooled five PCOS trials of GLP-1 receptor agonists and reported the following pooled effect sizes:

• ~28% reduction in free testosterone
• ~68% improvement in menstrual regularity
• ~31% improvement in HOMA-IR (a marker of insulin resistance)
• ~55% higher ovulation rates — with the largest improvements concentrated in patients who lost at least 10% of body weight

These are pooled trial endpoints, not individual guarantees. Individual response varies by phenotype, dose, duration, and adherence. But the direction and magnitude of the signal is consistent across the included studies — which is the key thing to take from a meta-analysis.

4. The 2025 UK real-world tirzepatide cohort

The largest single dataset of GLP-1 medications in PCOS to date is the 2025 UK real-world cohort: 4,241 women with PCOS prescribed tirzepatide between February 2024 and January 2025.

• Median weight loss: 18.81% at ten months
• Reached ≥5% loss: 96.58%
• Reached ≥10% loss: 90.8%
• Reached ≥15% loss: 75.96%

This is not a controlled clinical trial — it is real-world adherence with real-world dosing, real-world dropouts, and real-world plateaus baked in. The fact that PCOS women in the wild hit close to the SURMOUNT trial averages (20–22% at max dose in general-population trials) is itself noteworthy. PCOS appears to respond to tirzepatide at least as well as the general weight-loss population, and possibly better on the secondary endpoints (insulin, androgens, cycles) that matter most in PCOS specifically.

5. Semaglutide vs. tirzepatide — how to choose

The practical clinical choice in PCOS today is usually between semaglutide and tirzepatide. Both work; the magnitudes differ; the choice typically hinges on three personal factors.

Weight-loss magnitude

Semaglutide PCOS-specific cohorts and trials have typically reported 10–15% weight loss at six months. The UK tirzepatide cohort hit 18.81% median at ten months. If significant weight loss is the primary goal, tirzepatide's edge is real.

Fertility timeline

Semaglutide washout before active TTC is at least eight weeks (half-life ~7 days × 5, plus safety buffer). Tirzepatide washout is approximately four to five weeks. If TTC is in your near-term horizon, the shorter washout favors tirzepatide.

Cost

At direct-pay compounded pricing, tirzepatide is approximately 30–35% more expensive than semaglutide ($199/mo vs. $149/mo at TelePeptide founder rates). For most patients this is not the binding factor, but it does matter for some.

6. Microdose protocols for lean PCOS

Approximately 20–30% of women with PCOS have what is sometimes called the "lean phenotype" — a normal BMI alongside biochemical hyperandrogenism and irregular cycles. Standard-dose GLP-1 protocols are designed for patients who need significant weight loss. For lean PCOS, the calculus is different.

Microdose protocols use lower weekly doses (often 0.125–0.25 mg semaglutide or 1.25–2.5 mg tirzepatide) calibrated against the metabolic and cycle goals rather than scale change. The Cena meta-analysis showed testosterone reduction and cycle regularization at the lower end of the dose-response curve — major weight loss required higher doses, but the PCOS-specific benefits did not.

For lean PCOS, the protein floor (≥1.0–1.2 g/kg), resistance training, and weekly weight tracking become non-negotiable. The goal is metabolic and cycle improvement without driving below healthy weight.

7. What to expect by month — a realistic timeline

• Week 1–4: Appetite reduction. "Food noise" quieting. Minimal scale change. Fasting insulin starting to drop (you cannot feel it).
• Week 4–12: Cycle changes start. Many women see the first regular cycle in years in this window. Modest weight loss (3–7%).
• Month 3–6: Weight loss accelerates. The Cena meta-analysis numbers (28% free T reduction, 68% cycle regularity) typically land in this window. Plateau around month 4–5 is normal.
• Month 6–12: Full effect. UK cohort hit 18.81% by month 9–10 on tirzepatide. Hair, skin, and androgen-driven symptoms become visible (they lag because hair cycles are 3–6 months).

The most common mistake patients make is judging the protocol at week 4 by scale alone. The metabolic and cycle effects appear before the weight effects, and the visible androgen effects appear after. A reasonable evaluation cadence is week 4 for tolerability, week 8–12 for first labs, month 6 for full efficacy review.

8. TTC planning and pregnancy washout

GLP-1 receptor agonists are not used during conception, pregnancy, or breastfeeding. This is a categorical contraindication, not a gray area.

The washout windows:

• Semaglutide: ≥8 weeks before a planned pregnancy
• Tirzepatide: approximately 4–5 weeks before a planned pregnancy
• Liraglutide: short washout (a few days)

The strategic sequence many PCOS women use: GLP-1 for 6–12 months to improve weight and cycle regularity → planned washout → TTC. The 55% improved ovulation rate from the meta-analysis is the rationale — used correctly, the medication improves the pre-conception metabolic baseline, then exits before conception.

During washout, many clinicians bridge with metformin and/or myo-inositol to preserve insulin-sensitivity gains. Both have substantial safety data through TTC.

9. Side effects, contraindications, and safety monitoring

The side-effect profile of GLP-1s in PCOS mirrors the general-population profile. Common adverse events: nausea (20–40%), occasional vomiting and constipation, slowed gastric emptying. Most resolve as titration completes.

Serious but uncommon: pancreatitis, gallbladder disease (with rapid weight loss).

Absolute contraindications:

• Pregnancy and breastfeeding
• Personal or family history of medullary thyroid carcinoma or MEN-2
• Prior severe pancreatitis
• Significant gastroparesis

For PCOS women on oral contraceptive pills: GLP-1 slows gastric emptying and may reduce OCP absorption during dose escalation. Current guidance is to use a back-up barrier method during titration.

10. Where metformin fits — not either/or

Metformin and GLP-1s are increasingly complementary rather than alternatives. Metformin works peripherally on hepatic glucose production and skeletal-muscle insulin signaling; GLP-1s act centrally on appetite and peripherally on insulin secretion and tissue sensitivity. Stacking them is mechanistically reasonable.

Common clinical patterns: metformin alone for mild PCOS with modest weight goals; metformin + GLP-1 for significant weight goals or insufficient metformin response; metformin as a bridge during GLP-1 washout for TTC patients. The clinician decides based on the individual picture.

11. What to ask any prescriber before starting

1. What's the titration plan, and how is it calibrated to my response (not just a fixed schedule)?
2. What labs will be checked, and at what cadence?
3. If TTC is in my horizon, what's the washout plan?
4. Where is the medication compounded? Is the pharmacy 503A or 503B? How is quality monitored?
5. What's the plan when I plateau (which I will, around month 4–5)?
6. If side effects don't resolve, what's the de-escalation or switch plan?
7. How often will I have a clinician check-in, and how do I message between visits?

12. The TelePeptide PCOS program

The TelePeptide PCOS protocol uses compounded semaglutide ($149/mo at founder pricing) or compounded tirzepatide ($199/mo) with clinical reasoning calibrated to PCOS specifically. The clinician reviews insulin markers, androgen markers, and cycle history alongside weight when deciding on medication and dose.

We do not promise cycle restoration, ovulation, or any specific fertility outcome. We run a clinician-supervised metabolic protocol that addresses the underlying driver of PCOS and let the downstream effects follow. Patients with TTC plans get those plans built into the protocol from intake. The medication is not used during pregnancy or breastfeeding.